Skip to main content

Table 4 Meta-analysis in efficacy and safety of ivabradine in patients with stable coronary angina and heart failure

From: Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials

 

Ivabradine

 

Placebo

 

Odds ratio

P-value

I2 in %

Outcome

Event/Total, n/N

%

Event/total

%

M-H, random & Fixedb, 95% CI

Cardiovascular death

1247/18270

6.8

1227/18254

6.7

1.02(0.91–1.15)

0.74

51

All-cause mortality

1560/18270

8.5

1557/18254

8.5

1(0.91–1.10)

0.98

78

Hospital admissiona

1156/18270

6.3

1280/18254

7

0.94(0.71–1.25)

0.69

89

Coronary revascularization

717/15029

4.7

750/14990

5

0.93(0.77–1.11)

0.41

57

Phosphenes

601/12771

4.7

69/12804

5.3

7.77(4.4–14.6)

<0.00001

78

Symptomatic bradycardia

907/12771

7.1

142/12804

1.1

6.23(4.2–9.26)

<0.00001 1

71

Atrial fibrillation

814/12771

6.3

613/12804

4.7

1.35(1.21–1.51)

<0.00001

22

Blurred vision

134/12771

1

44/12804

0.3

3.07(2.18–4.32)

<0.00001

0

Infection& infestation

519/8709

5.9

555/8690

6.3

0.93(0.82–1.05)

0.26

0

Serious adverse event

2683/8709

31

2792/8690

32

0.97(0.85–1.11)

0.36

48

Cardiac disorder

2203/8709

2.5

2454/8690

2.8

0.85(0.65–1.11)

0.24

89

  1. CI Confidence Interval, a shows hospital admission for worsening or new onset of heart failure,bindicates the use of random effect model when I2 ≥ 50 and fixed effect if I2 < 50